Erudio Healtherudio.com
Drug
Ivonescimab trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying ivonescimab: HARMONi-3 and HARMONi-GI3. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 5 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| HARMONi-3 NCT05899608 · Summit Therapeutics | first-line metastatic non-small cell lung cancer | Phase 3 | 354 | 104 | Deep | Nov 15, 2026 | Preview |
| HARMONi-GI3 NCT07228832 · Summit Therapeutics | first-line metastatic colorectal cancer | Phase 3 | 19 | 10 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| I-SPY NCT01042379 · QuantumLeap Healthcare Collaborative DeepView → | early-stage or locally advanced breast cancer | Phase 2 | Deep | View | |||
| ARC-20 NCT05536141 · Arcus Biosciences, Inc. DeepView → | clear cell renal cell carcinoma and solid tumors | Phase 1 | Deep | View | |||
| HARMONi-7 NCT06767514 · Summit Therapeutics DeepView → | first-line metastatic NSCLC with high PD-L1 expression | Phase 3 | Deep | View | |||
| NCT06940518 NCT06940518 · M.D. Anderson Cancer Center FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT06478043 NCT06478043 · Zhejiang Cancer Hospital FocusedView → | second-line small-cell lung cancer | Phase 2 | Focused | View | |||